NCT05443841 Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
| NCT ID | NCT05443841 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Esophageal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 385 participants |
| Start Date | 2022-07-18 |
| Primary Completion | 2024-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 385 participants in total. It began in 2022-07-18 with a primary completion date of 2024-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis. Pleural lavage cytology (PLC) is reported to be associated with disease recurrence and patient survival in lung cancer, but the value is unclear in esophageal cancer. The aim of this study is to evaluate the value of PLC in esophageal cancer patient in terms of frequencies, association with patient survival, and efficacy of postoperative treatment.
Eligibility Criteria
Inclusion Criteria: * esophageal cancer with histological confirmation before treatment. * resectable esophageal cancer with clinical T1-4a/N0-3/M0 staging * potential R0 resection * no history of other malignancies Exclusion Criteria: * severe major organ dysfunction (American society of anesthesiologisits score \>3 ) * patients underwent ESD or EMR * pleural lavage is unavailable due to adhesions
Contact & Investigator
Haiquan Chen, MD
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT05443841 clinical trial?
This trial is open to participants of all sexes, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05443841 currently recruiting?
Yes, NCT05443841 is actively recruiting participants. Contact the research team at lb0256327@hotmail.com for enrollment information.
Where is the NCT05443841 trial being conducted?
This trial is being conducted at Hefei, China, Shijiazhuang, China, Zhengzhou, China, Nantong, China and 7 additional locations.
Who is sponsoring the NCT05443841 clinical trial?
NCT05443841 is sponsored by Fudan University. The principal investigator is Haiquan Chen, MD at Fudan University. The trial plans to enroll 385 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.